Europe
Diabetes player Novo Nordisk cut a deal this week, announcing a settlement agreement to put an end to a lawsuit filed in January 2017 by American Depository Receipt investors.
The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
September 24 is World Cancer Research Day, a time for patients, caregivers and companies on the forefront of cancer R&D to look back and look ahead.
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
GlaxoSmithKline Chief Executive Officer Emma Walmsley faces renewed calls for her ouster after Bluebell Capital Partners has taken a £10 million (about $13.7 million) stake in the company.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Monoclonal antibodies play a key role in the treatment of COVID-19, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies.
Codagenix Inc. announced positive safety and immunogenicity data from a Phase I dose-escalation trial of its single-dose intranasal COVI-VAC vaccine.
French artificial heart maker Carmat announced Tuesday that it had successfully implanted its Aeson artificial heart into the chest cavity of a 57-year-old woman.
PRESS RELEASES